Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

least two month Ruxolitinib treatment prior to transplantation DAC+BF as myeloablative conditioning regimen CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of

  • 0 views
  • 05 May, 2022
  • 1 location
Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation in patients with chronic granulomatous disease

stem cell transplantation
g-csf
gcsf
  • 0 views
  • 04 Mar, 2022
  • 1 location
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1)

A randomized controlled study to assess the safety and efficacy and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.

  • 47 views
  • 26 Mar, 2022
  • 17 locations
Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT in Nijmegen breakage syndrome

  • 0 views
  • 25 Jan, 2021
  • 1 location
Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting

Mucositis is a very common complication in bone marrow transplant setting. It is a result of injury to the gut caused by high dose chemotherapy. Currently there are no universal protocols that have been accepted as a standard to prevent and treat mucositis in the transplant setting. Post transplant upto …

  • 0 views
  • 30 May, 2021
  • 1 location
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.

cell transplantation
b-cell acute lymphoblastic leukemia
busulfan
fludarabine
thymoglobulin
  • 437 views
  • 25 Jan, 2021
  • 162 locations
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

effectiveness of two haemopoietic stem cell transplant (HSCT) conditioning regimens of different intensity: conventional myeloablative conditioning (MAC) with busulfan/cyclophosphamide and reduced intensity

busulfan
residual tumor
gemtuzumab
daunorubicin
neoadjuvant therapy
  • 0 views
  • 26 Jan, 2022
  • 69 locations
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

The purpose of this study is to compare safety and efficacy of reduced-intensity conditioning and myeloablative conditioning regimens prior to HSCT in high-risk AML/MDS pediatric and young adult

melphalan
hydroxyurea
busulfan
residual tumor
aml/mds
  • 40 views
  • 22 Mar, 2022
  • 1 location
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT

To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptive immunotherapy improve cGvHD/disease free survival after allogeneic HSCT in patients affected by high-risk acute leukemias or other hematologic malignancy where HSCT is indicated.

multiple myeloma
myeloid leukemia
acute leukemia
leukemia
hematologic malignancy
  • 6 views
  • 09 Feb, 2022
  • 1 location
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease (NYMC-571)

This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of …

cell transplantation
hydroxyurea
hemoglobin c disease
sickle hemoglobin
blood transfusion
  • 18 views
  • 22 Apr, 2022
  • 3 locations